RDH14: A Potential Drug Target Or Biomarker (G57665)

Target Name: RDH14

NCBI ID: G57665

RDH14

RDH14: A Potential Drug Target Or Biomarker

RDH14 (Retinol Dehydrogenase 14) is a gene that encodes a protein involved in the metabolism of retinol, a form of vitamin A. Retinol is a crucial nutrient that plays a vital role in various cellular processes, including vision, skin health, and wound healing. The function of RDH14, as well as other genes involved in retinol metabolism, has been the subject of intense research in recent years, and has the potential to be a drug target or biomarker.

The gene encoding RDH14 is located on chromosome 14 of the human genome, and its function has been extensively studied in the context of retinol metabolism. The protein produced by RDH14 is involved in the conversion of retinol to its active form, known as retinyl ester, which is then used by other enzymes in the retinol pathway to perform various functions.

One of the key functions of RDH14 is its role in the production of retinyl ester, which is the most active form of retinol. This protein is synthesized by the enzyme 2-oxoglutarate dehydrogenase (2-OGD), which is also encoded by gene GSTP1 (Glutathione S-Transferase P1). 2-OGD is a critical enzyme in the retinol pathway, as it converts 2-oxoglutarate, a precursor molecule, to 2-OGD-riboside, which is then converted to retinyl ester by the enzyme RDH14.

In addition to its role in the production of retinyl ester, RDH14 is also involved in the metabolism of other molecules in the retinol pathway. For example, this protein is involved in the conversion of retinol to retinyl 6-phosphate, a molecule that is then used by the enzyme tyrosine aminotransferase (TAT) to synthesize the protein tyrosine. Another function of RDH14 is its role in the production of retinyl 8-epoxide, a molecule that is involved in the regulation of cell signaling pathways.

The potential implications of RDH14 as a drug target or biomarker are significant. If an inhibitor of RDH14 were to be developed and administered to patients, it could potentially slow down or stop the production of retinyl ester and reduce the levels of active vitamin A in the body. This could have a beneficial effect on various conditions that are caused or exacerbated by vitamin A deficiencies, such as dry skin, rough skin, and night blindness.

In addition to its potential use as a drug, RDH14 may also be used as a biomarker to diagnose or monitor certain conditions. For example, individuals with certain genetic mutations, such as those encoding diseases like rosacea or macular degeneration, may have reduced levels of RDH14 and may be at risk for developing these conditions. By measuring the levels of RDH14 in these individuals, doctors could potentially identify potential therapeutic interventions or screen for early signs of these conditions.

Overall, the function of RDH14 as a protein involved in the metabolism of retinol is a topic of intense interest and has the potential to be a drug target or biomarker. Further research is needed to fully understand the role of this protein in various cellular processes and to develop effective treatments or diagnostics based on its properties.

Protein Name: Retinol Dehydrogenase 14

Functions: Retinol dehydrogenase with a clear preference for NADP. Displays high activity towards 9-cis, 11-cis and all-trans-retinol. Shows a very weak activity towards 13-cis-retinol. Has no activity towards steroid

The "RDH14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RDH14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets